<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03385031</url>
  </required_header>
  <id_info>
    <org_study_id>P0268</org_study_id>
    <nct_id>NCT03385031</nct_id>
  </id_info>
  <brief_title>Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients</brief_title>
  <official_title>Prospective Validation of 3D Dose Metrics as Selection Criteria for Adaptive Radiotherapy in Breast Cancer Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Maastricht Radiation Oncology</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Maastricht Radiation Oncology</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      In a retrospective study the investigators defined quantitative action levels based on dose
      and volume measures for adaptive radiation therapy in breast cancer patients (Zegers et al.
      Acta Oncol 2017). The aim of this study is to validate these parameters in a prospective
      study.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      During radiotherapy, changes in patient anatomy or positioning can result into differences in
      dose deposition, which is the main factor influencing tumor control or side-effects.
      Dose-guided radiation therapy is the systematic evaluation of the dose delivery during
      treatment for an individual patient with the aim to adapt the treatment if needed.
      Recalculation of the dose during treatment can be performed using the imaging information
      during treatment. In a retrospective study the investigators defined quantitative action
      levels based on dose and volume measures for adaptive radiation therapy in breast cancer
      patients (Zegers et al. Acta Oncol 2017). The aim of this study is to validate these
      parameters in a prospective study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 1, 2018</start_date>
  <completion_date type="Anticipated">August 1, 2018</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2018</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Validation of quantitative action levels</measure>
    <time_frame>3-4 weeks (time between 1st and last fraction of radiotherapy)</time_frame>
    <description>Evaluation of DVH parameters on the CBCT of the 1st and last fraction of radiotherapy treatment. Evaluate if the changes during treatment are within the thresholds set by the previous retrospective study; are parameters within predefined criteria yes/no</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Automatic re-delineation</measure>
    <time_frame>3-4 weeks (time between 1st and last fraction or radiotherapy)</time_frame>
    <description>Evaluation of automatic re-delineation of the target volume against manual re-delineation by a radiotherapy oncologist on the CBCT of the 1st and last fraction of radiotherapy treatment.</description>
  </secondary_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Breast Cancer</condition>
  <arm_group>
    <arm_group_label>group 1</arm_group_label>
    <description>whole breast irradiation, CBCT imaging at first and last fraction of radiotherapy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 2</arm_group_label>
    <description>simultaneous integrated boost, CBCT imaging at first and last fraction of radiotherapy treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>group 3</arm_group_label>
    <description>patients with seroma at start radiation treatment (whole breast irradiation or simultaneous integrated boost), CBCT imaging at first and last fraction of radiotherapy treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>CBCT imaging</intervention_name>
    <description>CBCT imaging at first and last fraction of radiotherapy treatment</description>
    <arm_group_label>group 1</arm_group_label>
    <arm_group_label>group 2</arm_group_label>
    <arm_group_label>group 3</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        1. Whole breast irradiation (N=10)

          2. Simultaneous integrated boost (N=10)

          3. Patients with seroma at start radiation treatment (N=10)
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Breast cancer patients

          -  Planned for external beam radiation treatment.

          -  Whole breast irradiation or Simultaneous integrated boost
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_official>
    <last_name>Karen Zegers, PHD</last_name>
    <role>Principal Investigator</role>
    <affiliation>researcher</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Karen Zegers, PHD</last_name>
    <phone>+31-884455875</phone>
    <email>karen.zegers@maastro.nl</email>
  </overall_contact>
  <location>
    <facility>
      <name>Maastricht Radiation Oncology</name>
      <address>
        <city>Maastricht</city>
        <zip>6202 AZ</zip>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Netherlands</country>
  </location_countries>
  <link>
    <url>https://www.ncbi.nlm.nih.gov/pubmed/?term=(Zegers+et+al.+Acta+Oncol+2017)</url>
    <description>Three-dimensional dose evaluation in breast cancer patients to define decision criteria for adaptive radiotherapy.</description>
  </link>
  <reference>
    <citation>Zegers CML, Baeza JA, van Elmpt W, Murrer LHP, Verhoeven K, Boersma L, Verhaegen F, Nijsten SMJJG. Three-dimensional dose evaluation in breast cancer patients to define decision criteria for adaptive radiotherapy. Acta Oncol. 2017 Nov;56(11):1487-1494. doi: 10.1080/0284186X.2017.1349334. Epub 2017 Aug 29.</citation>
    <PMID>28849731</PMID>
  </reference>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>December 20, 2017</study_first_submitted>
  <study_first_submitted_qc>December 20, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">December 28, 2017</study_first_posted>
  <last_update_submitted>May 14, 2018</last_update_submitted>
  <last_update_submitted_qc>May 14, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 17, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Dose-guided radiation therapy</keyword>
  <keyword>CBCT</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

